Navigation Links
Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
Date:9/10/2009

100 will be administered intravenously for three out of four weeks. Once the maximum tolerated dose (MTD) has been established, additional subjects with specific diagnoses of either breast, ovarian, endometrial, pancreatic or prostate cancer will be enrolled and dosed at the MTD. Additionally, patients with other types of cancer may be added based on activity observed in previous cohorts. More information on the trial can be found at www.clinicaltrials.gov.

Results from preclinical studies of EP-100 have shown that the drug regresses established tumors in breast, prostate, ovarian and endometrial cancer xenografts in mice. The results in ovarian cancer were presented at the 2009 American Association for Cancer Research (AACR) Annual Meeting. In in vivo studies, the efficacy of EP-100 in comparison to saline or untargeted membrane-disrupting peptide or cisplatinum was studied in an ovarian cancer xenograft model (OVCAR-3). EP-100 regressed established OVCAR-3 xenografts following weekly injections at doses as low as 0.2 mg/kg bodyweight (p<0.03 vs. baseline). In comparison, tumor growth was observed across the saline control, untargeted membrane-disrupting peptide and cisplatinum arms. In addition, in the EP-100 arm tumor volumes, weights and CA125 (a clinical biomarker for ovarian cancer) were reduced. LHRH receptor levels were also reduced and PET imaging revealed that EP-100 treated tumors became necrotic, lacking viable tumor cells after treatment. EP-100 was well tolerated in all treated groups.

Esperance is using its CLYP(TM) technology to develop a robust portfolio of novel tMDPs to selectively destroy cancer cells that express target receptors. In addition to EP-100, Esperance has other drug candidates in preclinical stages, all of which have a unique targeting mechanism of action whereby candidates bind specifically a
'/>"/>

SOURCE Esperance Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 ... based on the products of cells grown under ... entered into an international license agreement with Suneva ... proprietary multipotent cell conditioned media (CCM). ... existing license between Histogen and Suneva Medical, through ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research ... ALQA). Alliqua is an emerging biomedical company acquiring, ... the wound care market. , Free report download: ... was restructured with a seasoned management team and ... become a leading provider of wound care products. ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader ... as the new Director of Product Strategy. In this ... as well as iLab sub-teams to guide in the ... to ensure that iLab provides the maximum possible benefit ... user-friendly, and high-impact solution in the world. , ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ... to challenges related to patient safety, clinical outcomes, ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Revenue Grows 15 Percent Quarter-over-Quarter -, PALO ALTO, Calif., ... reported financial results for the second quarter,ended June 30, 2008., ... reported a net loss of,$4.3 million, or $0.07 per share. ... per share, for the prior quarter ended March 31, 2008 ...
... 31 Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ) ... overview at the Bank of America 2008 Specialty,Pharmaceuticals ... ET at the,Southampton Inn, Long Island, NY., ... presentation can be,accessed under "Calendar of Events" in ...
... 31 Vista Partners announced today,that it has ... which target billion dollar markets, are progressing through,the ... present Phase 2 results for,Convivia(TM) sometime in the ... approval,of Delayed Release (DR) Cysteamine for the treatment ...
Cached Biology Technology:CV Therapeutics Reports 2008 Second Quarter Financial Results 2CV Therapeutics Reports 2008 Second Quarter Financial Results 3CV Therapeutics Reports 2008 Second Quarter Financial Results 4CV Therapeutics Reports 2008 Second Quarter Financial Results 5CV Therapeutics Reports 2008 Second Quarter Financial Results 6CV Therapeutics Reports 2008 Second Quarter Financial Results 7Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP) 2
(Date:4/15/2014)... Academy of Arts and Sciences (KNAW) has announced the ... awarded prestigious Heineken Prizes (one million US dollars prize ... for their great merits to science. , This year ... awarded to the Austrian-American chemist Erwin Chargaff in 1964. ... Prizes to the following laureates: , Christopher ...
(Date:4/15/2014)... 2050, deforestation could cause temperatures in the Congo ... would intensify warming caused by greenhouse gases by ... the University of Leuven, Belgium. , Explosive population ... destruction of tropical rainforests in Central Africa. A ... examined how these practices will affect longer-term temperatures ...
(Date:4/15/2014)... of Adelaide research into parasites of cuttlefish, squid ... astonishing life cycles, and shown how they may ... Researcher Dr Sarah Catalano has described 10 new ... the kidneys of cephalopods (cuttlefish, squid and octopus). ... to be described from Australian waters. , ...
Breaking Biology News(10 mins):Five scientists awarded prestigious Heineken Prizes 2Study: Deforestation could intensify climate change in Congo Basin by half 2Bizarre parasite may provide cuttlefish clues 2
... Human Genome Research Institute (NHGRI), one of the National ... of sequencing targets, with an emphasis on enhancing the ... differences between individuals influence the risk of health and ... Research, which is a federally chartered committee that advises ...
... Comprehensive Cancer Center say that just one, single, malfunctioning ... discovery offers new insight into the development of some ... time underscores the powerful role that these tiny snippets ... in carcinogenesis. , "To the best of our ...
... Coast fever destroys the small farmer's dream of escaping poverty ... some $200 million annually, this tick-borne disease rages across a ... team of scientists has taken the first major step toward ... in the February 13-17 early online edition of the ...
Cached Biology News:NHGRI announces new sequencing targets 2NHGRI announces new sequencing targets 3NHGRI announces new sequencing targets 4Single microRNA causes cancer in transgenic mouse 2Single microRNA causes cancer in transgenic mouse 3Genomics-based vaccine could prevent deadly cattle disease 2Genomics-based vaccine could prevent deadly cattle disease 3